Top 10 Companies in the Hyaluronic Acid-based Biomaterials Market (2026): Leaders Shaping Global Biomedicine

MARKET INSIGHTS

Global hyaluronic acid-based biomaterials market size was valued at USD 204 million in 2024. The market is projected to grow from USD 211 million in 2025 to USD 254 million by 2034, exhibiting a CAGR of 3.2% during the forecast period.

Hyaluronic acid-based biomaterials are naturally occurring mucopolysaccharides that play a vital role in tissue hydration and lubrication. These biomaterials are widely used in medical applications such as orthopedic injections, ophthalmic surgery solutions, and cosmetic dermatology due to their excellent biocompatibility and viscoelastic properties. The market includes various grades of hyaluronic acid products, primarily categorized into cosmetic grade, food grade, and pharmaceutical grade formulations.

The market growth is driven by increasing demand for minimally invasive cosmetic procedures and rising applications in osteoarthritis treatment. However, the market faces challenges from alternative biomaterials and stringent regulatory requirements. China currently dominates the consumption landscape with 27% market share, while Bloomage BioTechnology leads production with 42% global market share. The expansion of aesthetic medicine in emerging economies and advancements in bioprocessing technologies present significant growth opportunities for market players.

Hyaluronic Acid-based Biomaterials Market – View in Detailed Research Report

Top 10 Companies in the Hyaluronic Acid-based Biomaterials Market

1. Bloomage BioTechnology

Headquarters: Shanghai, China
Key Offering: Pharmaceutical‑grade hyaluronic acid for viscosupplementation, ocular viscoelastic, and dermal fillers.

Bloomage has built a vertically integrated plant that can produce high‑molecular‑weight HA at yields exceeding 80%. The company’s focus on process automation has reduced production costs, enabling competitive pricing in both domestic and export markets. Bloomage’s recent launch of a cross‑linked HA derivative for long‑lasting dermal fillers has opened a new premium segment.

Sustainability & Growth Initiatives:

• Investment in recombinant fermentation to lower raw‑material dependency.
• Partnership with global distributors to expand reach in North America and Europe.
• Commitment to reducing CO₂ emissions by 30% across its supply chain by 2030.

2. Shandong Galaxy Bio-Tech

Headquarters: Qingdao, China
Key Offering: Cosmetic‑grade HA for dermal fillers and skincare formulations.

Galaxy Bio-Tech leverages a proprietary fermentation platform that delivers HA with a controlled molecular weight distribution, enhancing product performance. The company’s recent expansion into the U.S. market through a joint venture with a leading medical device distributor has increased its footprint in the high‑growth orthopedic segment.

Sustainability & Growth Initiatives:

• Adoption of a closed‑loop water recycling system in its production facilities.
• Development of a plant‑based extraction line to diversify raw‑material sources.
• Strategic acquisition of a European distribution network to strengthen market penetration.

3. Kewpie Corporation

Headquarters: Tokyo, Japan
Key Offering: Food‑grade HA for functional foods and nutraceuticals.

Kewpie’s long‑standing expertise in bioprocessing has positioned it as a trusted supplier for the food and beverage industry. The company’s recent introduction of a high‑purity, low‑molecular‑weight HA product has met the growing demand for gut‑health supplements.

Sustainability & Growth Initiatives:

• Implementation of a zero‑waste policy in its production lines.
• Collaboration with research institutions to develop next‑generation HA‑based functional ingredients.
• Expansion of its global sales network through digital marketing platforms.

4. Novozymes A/S

Headquarters: Copenhagen, Denmark
Key Offering: Enzymatic synthesis of HA for pharmaceutical and cosmetic applications.

Novozymes’ enzymatic approach offers a scalable alternative to traditional fermentation, providing precise control over HA chain length. The company’s recent partnership with a leading cosmetic brand has introduced a new line of cross‑linked HA fillers with extended residence time.

Sustainability & Growth Initiatives:

• Investment in bioreactor technologies that reduce energy consumption by 25%.
• Research into renewable feedstocks for enzyme production.
• Engagement with regulatory bodies to streamline approval pathways for enzyme‑derived HA.

5. Shiseido Company

Headquarters: Tokyo, Japan
Key Offering: Cosmetic‑grade HA for skincare and anti‑aging products.

Shiseido has integrated HA into its flagship skincare line, leveraging its reputation for high‑quality beauty products. The launch of a novel HA‑based serum with micro‑encapsulation technology has driven sales growth in the premium segment.

Sustainability & Growth Initiatives:

• Adoption of sustainable sourcing practices for raw materials.
• Development of biodegradable packaging for HA‑infused products.
• Expansion of e‑commerce channels to reach younger consumers.

6. China Eastar

Headquarters: Shanghai, China
Key Offering: Pharmaceutical‑grade HA for joint care and ophthalmic applications.

Eastar’s focus on cost‑effective production has allowed it to capture a significant share of the domestic market. The company’s recent investment in a high‑yield fermentation facility has improved margins while maintaining product quality.

Sustainability & Growth Initiatives:

• Implementation of a green chemistry program to reduce solvent usage.
• Partnership with universities to develop next‑generation HA formulations.
• Expansion of its export portfolio to Southeast Asia.

7. FocusChem Biotech

Headquarters: Guangzhou, China
Key Offering: Pharmaceutical‑grade HA for drug delivery and regenerative medicine.

FocusChem’s expertise in polymer chemistry has enabled it to produce HA with tailored physicochemical properties for specific therapeutic applications. The company’s recent collaboration with a biotech firm has introduced a HA‑based scaffold for tissue engineering.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources for its manufacturing plants.
• Development of a closed‑loop waste management system.
• Strategic alliance with international distributors to enhance market reach.

8. Shandong Topscience Biotech

Headquarters: Jinan, China
Key Offering: Cosmetic‑grade HA for dermal fillers and anti‑wrinkle treatments.

Topscience has focused on refining cross‑linking chemistry to produce HA fillers with improved stability. The company’s recent launch of a single‑dose, ready‑to‑inject product has simplified application procedures for clinicians.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient manufacturing processes.
• Investment in research for HA‑based anti‑aging peptides.
• Expansion of its online sales platform to target international markets.

9. QuFu GuangLong Biochem

Headquarters: Guangzhou, China
Key Offering: Pharmaceutical‑grade HA for joint health and ocular applications.

QuFu’s focus on high‑purity HA has positioned it as a preferred supplier for premium medical devices. The company’s recent partnership with a leading ophthalmology group has introduced a new line of viscoelastic agents for cataract surgery.

Sustainability & Growth Initiatives:

• Adoption of biodegradable packaging for HA products.
• Investment in renewable feedstock sourcing.
• Expansion of its distribution network across East Asia.

10. Weifang Lide Bioengineering

Headquarters: Weifang, China
Key Offering: Cosmetic‑grade HA for dermal fillers and skincare.

Lide Bioengineering has leveraged its strong R&D capabilities to produce HA with enhanced rheological properties. The company’s recent launch of a dual‑action HA‑serum has attracted attention from both dermatologists and consumers.

Sustainability & Growth Initiatives:

• Implementation of a closed‑loop water recycling system.
• Development of a plant‑based extraction line.
• Strategic partnerships with e‑commerce platforms to reach global consumers.

Download FREE Sample Report: Hyaluronic Acid-based Biomaterials Market – View in Detailed Research Report

Get Full Report: Hyaluronic Acid-based Biomaterials Market – View in Detailed Research Report

Market Outlook (2025‑2034)

Over the next decade, the market is expected to maintain a steady expansion trajectory. The cosmetic segment, driven by the global trend toward non‑surgical rejuvenation, will continue to command the largest share of demand. Orthopedic and ophthalmic applications will sustain moderate growth, supported by demographic shifts and the rising prevalence of degenerative joint conditions.

Future Trends

• Hybrid Product Development: Integration of HA with platelet‑rich plasma, stem cells, or gene‑editing vectors is poised to create multi‑functional therapeutics that combine joint protection with tissue regeneration.
• Smart Delivery Systems: Responsive HA matrices that release active agents in response to pH or enzymatic cues are under active development, promising targeted drug delivery in ocular and dermatological settings.
• Regulatory Harmonization: Global convergence of quality standards for HA production will reduce approval times for multinational manufacturers, facilitating faster market entry.
• Digital Health Integration: Remote monitoring of treatment outcomes using wearable sensors and AI analytics will enable personalized dosing regimens for HA injections.
• Sustainability Imperative: The shift toward plant‑based and recombinant HA production will lower environmental footprints and meet the expectations of eco‑conscious consumers and regulators alike.